14,962 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new stake in Catalent, Inc. (NYSE:CTLT) during the 4th quarter, Holdings Channel reports. The firm purchased 14,962 shares of the company’s stock, valued at approximately $6,720,000.

Other large investors also recently made changes to their positions in the company. Gladius Capital Management LP acquired a new stake in shares of Catalent in the third quarter valued at approximately $28,000. Cary Street Partners Investment Advisory LLC increased its stake in shares of Catalent by 1,162.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of Catalent during the third quarter valued at approximately $181,000. Foundry Partners LLC acquired a new position in shares of Catalent during the third quarter valued at approximately $206,000. Finally, Bank of Marin acquired a new position in shares of Catalent during the third quarter valued at approximately $230,000.

Catalent Trading Up 0.3 %

Shares of NYSE:CTLT opened at $56.53 on Wednesday. The company has a 50 day moving average price of $56.40 and a 200 day moving average price of $49.26. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $60.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The stock has a market capitalization of $10.23 billion, a price-to-earnings ratio of -8.31, a PEG ratio of 6.09 and a beta of 1.18.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business posted $0.62 EPS. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. On average, research analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Ratings Changes

CTLT has been the topic of a number of research analyst reports. UBS Group reiterated a “neutral” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reiterated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. StockNews.com initiated coverage on shares of Catalent in a research note on Sunday. They set a “sell” rating on the stock. Finally, Barclays raised their price objective on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.